中芯國際(00981.HK)股票交易異常波動 無應披露重大信息
格隆匯10月9日丨中芯國際(00981.HK)發佈公吿,公司股票於2024年9月30日、2024年10月8日和2024年10月9日連續三個交易日內收盤價格升幅偏離值累計超過30%,根據《上海證券交易所交易規則》《上海證券交易所科創板股票異常交易實時監控細則》的有關規定,屬於股票交易異常波動情形。
公司董事會確認,截至本公吿披露日,除已按規定披露的事項外,公司沒有任何根據《上海證券交易所科創板股票上市規則》(以下簡稱“《科創板上市規則》”)等有關規定應披露而未披露的事項。董事會也未獲悉根據《科創板上市規則》等有關規定應披露而未披露的、對公司股票及其衍生品種交易價格可能產生較大影響的信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.